The rollercoaster ride to anti-cancer antibodies

Nature Biotechnology

Volumn 21, Issue 5, 2003, Pages 510-511

  Weiner, Louis M ^a   Carter, Paul ^b  

^a FOX CHASE CANCER CENTER   (United States)

^b Seattle Genetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; CD20 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; FC RECEPTOR; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LM 609; N ACETYLGLUCOSAMINYLTRANSFERASE; TRASTUZUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

CANCER IMMUNOTHERAPY; CANCER RESEARCH; DRUG EFFICACY; DRUG RESEARCH; HUMAN; IMMUNOMODULATION; LYMPHOMA; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; SHORT SURVEY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; NEOPLASMS; PROTEIN ENGINEERING;

EID: 0037995718     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt0503-510     Document Type: Short Survey

References (4)

1. Köhler, G. & Milstein, C. Nature 256, 495-497 (1975).
2. Keystone Symposium: Antibody-Based Therapeutics for Cancer, Banff Centre, Banff, Alberta, Canada, February 4-9, 2003.
3. Clynes, R.A., Towers, T.L., Presta, L.G. & Ravetch, J.V. Nat. Medicine 6, 443-446 (2000).
4. Clynes, R., Takechi, Y., Moroi, Y., Houghton, A. & Ravetch, J.V. Proc. Natl. Acad. Sci. USA 95, 652-656 (1998).